Clean Science & Technology has made the audio recording of its earnings conference call for the first quarter of fiscal year 2027 (Q1 FY27) available to the public. The call, which discussed the company’s financial results for the quarter ended June 30, 2026, was held on August 1, 2026. This disclosure comes in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The audio file has been uploaded to the company’s official website, allowing investors and analysts to review management’s commentary on the recent financial performance. The filing was signed by Ruchita Vij, the Company Secretary and Compliance Officer, and submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE).

Q1 FY27 Financial Context

During the same quarter, Clean Science reported a net profit of ₹732 million, a decline from ₹765 million in the corresponding quarter of the previous year. Revenue from operations stood at ₹2.1 billion, down from ₹2.2 billion year-on-year. EBITDA contracted to ₹868.7 million from ₹1 billion, with the EBITDA margin slipping to 41.95% from 45.77%.

Accessing the Recording

Investors can access the earnings call recording directly via the link provided in the exchange filing. The document confirms that the recording is hosted on the company’s domain, ensuring transparency and ease of access for stakeholders interested in the detailed discussion surrounding the Q1 FY27 results.

Clean Science and Technology Limited reported its highest-ever consolidated sales in Q1FY27, reaching ₹2,684.32 million, a 10.5% year-on-year increase from ₹2,428.69 million in Q1FY26. While standalone revenue declined 5.8% to ₹2,071.04 million due to global headwinds, the consolidated group delivered robust growth driven by its subsidiary, Clean Fino-Chem Limited. Consolidated net profit rose 4.7% to ₹733.50 million, compared to ₹700.63 million in the prior year. The Board of Directors approved these unaudited results on August 1, 2026, following a limited review by statutory auditors Price Waterhouse Chartered Accountants LLP.

Financial Performance

The divergence between standalone and consolidated figures highlights the growing contribution of subsidiaries. Standalone EBITDA margin contracted to 42.7% from 46.4% in Q1FY26, while consolidated EBITDA margin stood at 36.5%, down from 41.6%. However, consolidated profit before tax (PBT) grew 3.2% to ₹975.51 million. Other income provided a significant buffer, contributing ₹213.85 million to standalone total income, up from ₹129.24 million previously.

Raw material costs accounted for 34.6% of standalone revenue, up from 32.5% in Q1FY26. Power and fuel costs rose to 10.8% from 9.2%. Despite these pressures, the company maintained a zero-debt status and strong return on capital employed (RoCE) of 39.4% for FY26.

Strategic Initiatives and Capex

Clean Science incurred approximately ₹1,000 crore in capital expenditure during Q1FY27, primarily invested in Clean Fino-Chem Limited. The company is establishing a wholly-owned subsidiary in the Netherlands, potentially named Clean Science BV, with an initial capital infusion of EUR 50,000. This entity will focus on distributing specialty chemicals in Europe, strengthening customer proximity and accelerating global growth. Additionally, Performance Chemical 2 is expected to be commercialized by Q3FY27.

What the Numbers Show

The company’s strategy of diversifying through subsidiaries is yielding tangible results. While the parent entity faced margin compression due to higher input costs, the consolidated group achieved record sales. The strategic collaboration with Swiss technology partner Geneus Chem AG has helped de-risk product concentration; the top four legacy products’ contribution declined from ~85% in Q4FY23 to ~60% in Q1FY27. HALS now accounts for 22% of sales, indicating successful portfolio expansion into high-value specialty chemicals.